Beilstein Arch. 2022, 202250. https://doi.org/10.3762/bxiv.2022.50.v1
Published 20 Jun 2022
A practically convenient and streamlined protocol for trans-diastereoselective introduction of an aryl substituent at position 4 of 1,4-dihydroisoquinol-3-one (1,4-DHIQ) scaffold is presented. The protocol involves direct Regitz diazo transfer onto readily available 3(2H)-isoquinolones followed by TfOH-promoted hydroarylation by an arene molecule. Screening of the novel 1,2,4-trisubstituted 1,4-DHIQs against cancer cell lines confirmed high cytotoxicity of selected analogs, which validates this new chemotype for further investigation as anticancer cytotoxic agents.
Keywords: heterocyclic diazo compounds; Regitz diazo transfer; 1,4-dihydroisoquinol-3-one; triflic acid; hydroarylation
|Format: DOCX||Size: 14.7 MB||Download|
When a peer-reviewed version of this preprint is available, this information will be updated in the information box above. If no peer-reviewed version is available, please cite this preprint using the following information:
Dar'in, D.; Kantin, G.; Bunev, A.; Krasavin, M. Beilstein Arch. 2022, 202250. doi:10.3762/bxiv.2022.50.v1
|Download RIS (Reference Manager)||Download BIB (BIBTEX)|
© 2022 Dar'in et al.; licensee Beilstein-Institut.
This is an open access work licensed under the terms of the Beilstein-Institut Open Access License Agreement (https://www.beilstein-archives.org/xiv/terms), which is identical to the Creative Commons Attribution 4.0 International License (https://creativecommons.org/licenses/by/4.0). The reuse of material under this license requires that the author(s), source and license are credited. Third-party material in this work could be subject to other licenses (typically indicated in the credit line), and in this case, users are required to obtain permission from the license holder to reuse the material.